Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (January 2019)
20 slides from Imugene's investor presentation, Jan 10, 2019
Slide 1: Harnessing B-Cells for Cancer Immunotherapy
For personal use only HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY Leslie Chong Managing Director & CEO January 2019
Slide 2: Notice: Forward Looking Statements
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY N O T I C E : F O R W A R D L O O K I N G S TAT E M E N T S For personal use only Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, ex
Slide 3: Executive Summary
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY EXECUTIVE SUMMARY For personal use only Investment Highlights Imugene B-cell Vaccine Pipeline Experienced Management 01 02 03 & Board • Novel immuno-oncology B-cell peptide • Phase 1 clinical data in Her-2 breast • Meeting milestones vaccine technology and
Slide 4: A Team with a Track Record in Drug Development
INVESTOR PRESENTATION A TEAM WITH A TRACK RECORD IN DRUG DEVELOPMENT For personal use only Leslie Chong Paul Hopper Dr Axel Hoos Mr Charles Walker SYDNEY, AU SYDNEY, AU PHILADELPHIA, USA BRISBANE, AU Managing Director & CEO Executive Chairman Non-Executive Director Non-Executive Director • Over 20 y
Slide 5: Imugene Scientific Advisory Board
INVESTOR PRESENTATION IMUGENE SCIENTIFIC ADVISORY BOARD For personal use only Prof. Josep Tabernero Prof Pravin Kaumaya Dr. Michael Galigiuri VALL D’HEBRON, BARCELONA, Prof Tanios BekaiI Saab OHIO STATE UNIVERSITY, USA CITY OF HOPE, USA SPAIN MAYO CLINIC, USA • Prof of Medicine • President of Europe
Slide 6: Imugene develops vaccines to boost and direct the immune system
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY For personal use only Imugene develops vaccines to boost and direct the body’s immune system to specifically target and attack cancer cells 6
Slide 7: Is there a better way to make antibodies to treat cancer?
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY For personal use only IS THERE A BETTER WAY TO MAKE Monoclonal antibodies are ANTIBODIES Using B-cells manufactured in a facility TO TREAT in your body For example, Merck’s CANCER? Teaching B-cells to PD-1 inhibitor Keytruda® make antibodies using peptide
Slide 8: HER-Vaxx Mimotope: Mechanism of Action
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY HER-VAXX MIMOTOPE: MECHANISM OF ACTION? For personal use only Peptides “mimic” the epitope HER-VAXX ANTIBODY TUMOR SECRETION CELL Via helper T-cells HER-2/NEU 3 PEPTIDES HER-VAXX B-CELL IMMUNOTHERAPY ACTIVATION Epitope = Antibody Binding Site B CELL HER-Va
Slide 9: Current Phase 1b/2, in Gastric Cancer: Phase 1b
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY CURRENT PHASE 1B/2, IN GASTRIC CANCER For personal use only Phase 1b - Complete 2H, 2017 PHASE 1B PATIENTS ENROLLED Trial Patients Study Endpoints Study Results • Phase 1b • Gastric HER-Vaxx in • Recommended • 50 µg selected as the • Open label Cancer comb
Slide 10: Current Phase 1b/2, in Gastric Cancer: Phase 2
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY CURRENT PHASE 1B/2, IN GASTRIC CANCER For personal use only Phase 2 1H, 2019: COMMENCE PHASE 2 Trial Patients Study Primary Endpoints • Phase 2 • Gastric Randomized • OS • Open label Cancer HER-Vaxx in combination • PFS • Up to 70 with standard of care TBD
Slide 11: Strategic Acquisition
Three year 11 HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY R&D contract with access to Ohio translational labs For personal use only Access to experience and expertise with Prof. Pravin Kaumaya and team Six additional clinical candidates Her-1, Her-2, Her- STRATEGIC 3, VEGF, IGF-1R Six patent AQUISIT
Slide 12: Could Precision-Engineered Peptide Epitopes/Vaccines Be the Key to a Cancer Cure?
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY COULD PRECISION- For personal use only ENGINEERED PEPTIDE EPITOPES/VACCINES BE THE KEY TO A CANCER CURE? “Combination cancer vaccines with peptide mimics have the potential to treat existing cancer and prevent its reoccurrence.” PROF PRAVIN KAUMAYA OHIO ST
Slide 13: Imugene Pipeline
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY IMUGENE PIPELINE For personal use only Clinic or Program Pre-clinical Phase 1 Phase 2 Clinic-ready HER-Vaxx (HER2) B-Vaxx (HER2) KEY-Vaxx (PD-1) Her-2 & PD-1 Combo 13
Slide 14: Imugene Pipeline: Discovery Programs
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY IMUGENE PIPELINE For personal use only Discovery Program Pre-clinical ID of candidate Pipeline Her-1 (EGFR) Her-3 IGF-1R VEGF Combination (numerous) PD-L1 14
Slide 15: Why Select & Target PD-1 for B-Cell Vaccination?
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY WHY SELECT & TARGET PD-1 FOR B-CELL VACCINATION? For personal use only Monoclonal antibody immunotherapies Keytruda® (Merck) The combination of the and Opdivo® (BMS) PD-1 vaccine with the targeting PD-1 sold acquired Phase II Her-2 USD$3.8B and $4.9B, vacc
Slide 16: PD-1/HER-2 Vaccine Combination
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY PD-1/HER-2 VACCINE COMBINATION For personal use only Active in model of colorectal cancer with % Cancer growth inhibition in colorectal cancer model no signs of toxicity PD-1 vaccine plus Her-2 vaccine 90% All mice vaccinated over a period of 9 weeks showe
Slide 17: PD-1 KEY-Vaxx Vaccine Phase Development Path 2018-2019
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY PD-1 ‘KEY-VAXX’ VACCINE PHASE 1 DEVELOPMENT PATH 2018-2019 For personal use only PRE-CLINICAL MILSTONES PD-1 Finalise 2019: candidate CMC Formal FDA/IND regulatory IND Commence vaccine manufacturing pre-clinical granted submissions Phase 1 identified Phase
Slide 18: Financial Summary
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY FINANCIAL SUMMARY For personal use only NO. OF EXERCISE Options on issue OPTIONS PRICE EXPIRY Market Cap Listed: (IMUOA) 242.5M $0.026 30/11/2020 $75.8M AUD Listed:(IMUOB) 248.3M $0.04 30/11/2021 $54.5M USD Ordinary shares Unlisted: 59.5M $0.0247* 09/03/20
Slide 19: Executive Summary
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY EXECUTIVE SUMMARY For personal use only Investment Highlights Imugene B-cell Vaccine Pipeline Experienced Management 01 02 03 & Board • Novel immuno-oncology B-cell peptide • Phase 1 clinical data in Her-2 breast • Meeting milestones vaccine technology and
Slide 20: For personal use only
For personal use only Leslie Chong Managing Director & CEO leslie.chong@imugene.com +61 458 040 433